• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝炎肝移植受者的转录组变化表明伤口愈合失调。

Transcriptomic changes in liver transplant recipients with non-alcoholic steatohepatitis indicate dysregulation of wound healing.

机构信息

Computational Biology Program, Ontario Institute for Cancer Research, Toronto, ON, Canada.

Multi-Organ Transplant Program, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.

出版信息

Front Endocrinol (Lausanne). 2023 May 8;14:1111614. doi: 10.3389/fendo.2023.1111614. eCollection 2023.

DOI:10.3389/fendo.2023.1111614
PMID:37223041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10200958/
Abstract

BACKGROUND

Non-alcoholic steatohepatitis (NASH) has become a leading indication for liver transplantation. However, it often recurs in the graft and can also arise in individuals transplanted for other indications. Post-transplant NASH (PT-NASH) is more aggressive and leads to accelerated fibrosis. The mechanistic basis of PT-NASH has not yet been defined and no specific therapeutic strategies are currently available.

METHODS

Here, we profiled the transcriptomes of livers with PT-NASH from liver transplant recipients to identify dysregulated genes, pathways, and molecular interaction networks.

RESULTS

Transcriptomic changes in the PI3K-Akt pathway were observed in association with metabolic alterations in PT-NASH. Other significant changes in gene expression were associated with DNA replication, cell cycle, extracellular matrix organization, and wound healing. A systematic comparison with non-transplant NASH (NT-NASH) liver transcriptomes indicated an increased activation of wound healing and angiogenesis pathways in the post-transplant condition.

CONCLUSION

Beyond altered lipid metabolism, dysregulation of wound healing and tissue repair mechanisms may contribute to the accelerated development of fibrosis associated with PT-NASH. This presents an attractive therapeutic avenue to explore for PT-NASH to optimize the benefit and survival of the graft.

摘要

背景

非酒精性脂肪性肝炎(NASH)已成为肝移植的主要适应证。然而,它常在移植物中复发,也可能在因其他适应证而接受移植的个体中出现。移植后 NASH(PT-NASH)更为侵袭性,并导致纤维化加速。PT-NASH 的机制基础尚未明确,目前尚无特定的治疗策略。

方法

在这里,我们对来自肝移植受者的 PT-NASH 肝脏进行了转录组谱分析,以鉴定失调的基因、途径和分子相互作用网络。

结果

与 PT-NASH 中的代谢改变相关,观察到 PI3K-Akt 途径的转录组变化。其他显著的基因表达变化与 DNA 复制、细胞周期、细胞外基质组织和伤口愈合有关。与非移植 NASH(NT-NASH)肝脏转录组的系统比较表明,在移植后条件下,伤口愈合和血管生成途径的激活增加。

结论

除了脂质代谢改变之外,伤口愈合和组织修复机制的失调可能导致与 PT-NASH 相关的纤维化加速发展。这为探索 PT-NASH 的治疗途径提供了一个有吸引力的方向,以优化移植物的获益和存活率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0de/10200958/8fbe09fb95d9/fendo-14-1111614-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0de/10200958/8fbe09fb95d9/fendo-14-1111614-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0de/10200958/8fbe09fb95d9/fendo-14-1111614-g001.jpg

相似文献

1
Transcriptomic changes in liver transplant recipients with non-alcoholic steatohepatitis indicate dysregulation of wound healing.非酒精性脂肪性肝炎肝移植受者的转录组变化表明伤口愈合失调。
Front Endocrinol (Lausanne). 2023 May 8;14:1111614. doi: 10.3389/fendo.2023.1111614. eCollection 2023.
2
Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.非酒精性脂肪性肝炎肝移植的结果:一项欧洲肝移植登记研究。
J Hepatol. 2019 Aug;71(2):313-322. doi: 10.1016/j.jhep.2019.04.011. Epub 2019 May 7.
3
Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis.鉴定非酒精性脂肪性肝炎相关的转录组特征和关键途径。
Endocrine. 2021 Jul;73(1):52-64. doi: 10.1007/s12020-021-02716-y. Epub 2021 Apr 10.
4
Suppression of insulin-induced gene 1 (INSIG1) function promotes hepatic lipid remodelling and restrains NASH progression.抑制胰岛素诱导基因 1(INSIG1)的功能可促进肝脏脂质重塑并抑制 NASH 进展。
Mol Metab. 2021 Jun;48:101210. doi: 10.1016/j.molmet.2021.101210. Epub 2021 Mar 17.
5
Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis.非酒精性脂肪性肝炎患者肝移植术后新发2型糖尿病的风险
BMC Gastroenterol. 2015 Dec 15;15:175. doi: 10.1186/s12876-015-0407-y.
6
Clinicopathologic features of de novo non-alcoholic steatohepatitis in the post-transplant setting.移植后新发非酒精性脂肪性肝炎的临床病理特征。
Diagn Pathol. 2022 Aug 10;17(1):65. doi: 10.1186/s13000-022-01247-y.
7
Non-alcoholic fatty liver disease and liver transplantation.非酒精性脂肪性肝病与肝移植
Metabolism. 2016 Aug;65(8):1208-23. doi: 10.1016/j.metabol.2016.02.013. Epub 2016 Mar 3.
8
Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).血栓反应蛋白-1 是非酒精性脂肪性肝炎(NASH)的关键调节因子。
PLoS One. 2019 Dec 31;14(12):e0226854. doi: 10.1371/journal.pone.0226854. eCollection 2019.
9
Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis.与胰岛素抵抗指数相关的肝脏转录组特征解释了早期非酒精性脂肪性肝病的发病机制。
Ann Hepatol. 2020 Sep-Oct;19(5):472-481. doi: 10.1016/j.aohep.2020.06.009. Epub 2020 Jul 15.
10
Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.在豚鼠模型中,非酒精性脂肪性肝炎的分子驱动因素在从轻度到晚期纤维化进展中持续存在。
Mol Genet Genomics. 2019 Jun;294(3):649-661. doi: 10.1007/s00438-019-01537-z. Epub 2019 Feb 13.

引用本文的文献

1
ChREBP is activated by reductive stress and mediates GCKR-associated metabolic traits.ChREBP 通过还原性应激被激活,并介导 GCKR 相关的代谢特征。
Cell Metab. 2024 Jan 2;36(1):144-158.e7. doi: 10.1016/j.cmet.2023.11.010. Epub 2023 Dec 14.

本文引用的文献

1
Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.肝移植后发生的非酒精性脂肪性肝病或非酒精性脂肪性肝炎的代谢机制与治疗。
Nat Rev Endocrinol. 2022 Oct;18(10):638-650. doi: 10.1038/s41574-022-00711-5. Epub 2022 Jul 15.
2
Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis.非酒精性脂肪性肝炎肝移植后患者生存的预测因素:一项系统评价和荟萃分析。
EClinicalMedicine. 2022 Jul 1;50:101534. doi: 10.1016/j.eclinm.2022.101534. eCollection 2022 Aug.
3
SOCS2 Suppresses Inflammation and Apoptosis during NASH Progression through Limiting NF-κB Activation in Macrophages.
SOCS2 通过限制巨噬细胞中 NF-κB 的激活来抑制 NASH 进展中的炎症和细胞凋亡。
Int J Biol Sci. 2021 Oct 11;17(15):4165-4175. doi: 10.7150/ijbs.63889. eCollection 2021.
4
The molecular phenotypes of injury, steatohepatitis, and fibrosis in liver transplant biopsies in the INTERLIVER study.INTERLIVER 研究中肝移植活检中损伤、脂肪性肝炎和纤维化的分子表型。
Am J Transplant. 2022 Mar;22(3):909-926. doi: 10.1111/ajt.16890. Epub 2021 Dec 3.
5
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.转录组学鉴定出血小板反应蛋白-2 是 NASH 和肝纤维化的生物标志物。
Hepatology. 2021 Nov;74(5):2452-2466. doi: 10.1002/hep.31995. Epub 2021 Aug 21.
6
Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.2 型糖尿病和肥胖症患者肝衰竭的代谢谱:从非酒精性脂肪性肝病到非酒精性脂肪性肝炎再到肝细胞癌。
Int J Mol Sci. 2021 Apr 26;22(9):4495. doi: 10.3390/ijms22094495.
7
Clinical and Genetic Risk Factors of Recurrent Nonalcoholic Fatty Liver Disease After Liver Transplantation.肝移植后复发性非酒精性脂肪性肝病的临床和遗传危险因素。
Clin Transl Gastroenterol. 2021 Feb 5;12(2):e00302. doi: 10.14309/ctg.0000000000000302.
8
Metabolic syndrome following liver transplantation in nonalcoholic steatohepatitis.非酒精性脂肪性肝炎患者肝移植后的代谢综合征
Transl Gastroenterol Hepatol. 2021 Jan 5;6:13. doi: 10.21037/tgh.2020.02.07. eCollection 2021.
9
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis.非酒精性脂肪性肝病谱中的转录组特征分析揭示了肝脂肪变性和纤维化的基因特征。
Sci Transl Med. 2020 Dec 2;12(572). doi: 10.1126/scitranslmed.aba4448.
10
Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice.髓过氧化物酶的治疗性靶向作用可减轻小鼠非酒精性脂肪性肝炎。
Hepatol Commun. 2020 Jul 29;4(10):1441-1458. doi: 10.1002/hep4.1566. eCollection 2020 Oct.